Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neuromed Pharmaceuticals
Vancouver, British Columbia, Canadaneuromedrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neuromed Pharmaceuticals developed small molecule drugs targeting neuronal calcium channels for neurological disorders. Its lead product was Exalgo™ (extended-release hydromorphone) for chronic pain. Exalgo™ demonstrated significant efficacy in reducing pain intensity in opioid-tolerant patients with chronic low back pain compared to placebo in a Phase 3 trial.
- Therapeutic areas
- PsychiatryNeurologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Novartis oncology collaboration via CombinatoRx platform post-mergervarious pharmaceutical manufacturer partnerships pre-merger
Beyond the preview
Go deeper on Neuromed Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuromed Pharmaceuticals.